{"id":91232,"date":"2026-11-16T15:37:00","date_gmt":"2026-11-16T15:37:00","guid":{"rendered":"https:\/\/english.saigonbiz.com\/vn\/?p=91232"},"modified":"2026-11-17T02:15:03","modified_gmt":"2026-11-17T02:15:03","slug":"anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/","title":{"rendered":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035"},"content":{"rendered":"<p><em>Lilly&#8217;s Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo&#8217;s Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and Deals<\/em><\/p>\n<p>Ottawa, Nov.  16, 2026  (GLOBE NEWSWIRE) &#8212; <img decoding=\"async\" height=\"62.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/8feae5d4-f0f7-40f0-a2af-11a041f11f9a\/image1.png\" width=\"190.0px\" data-dpi=\"96\" data-filename=\"image1.png\" \/><\/p>\n<p><i>The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and is projected to reach USD 64.96 billion by 2035 at a CAGR of 24.71%. Eli Lilly and Novo Nordisk dominate, while Pfizer, Roche, Amgen and a group of emerging developers are investing to win share in the next wave of therapies.<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"318.68px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/70960de1-d1b2-4092-8185-88a7cef28b4f\/image2.png\" width=\"566.56px\" data-dpi=\"72\" data-filename=\"image2.png\" \/><\/p>\n<p>Precedence Research today released updated company intelligence on the global <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HmKlT2aLuL5iZWkgDN9vEw0aYBALKCSw0G2cPb6vVQc25ug7leKW61gcGIkwuw_ln1JbiNQISwOVUhyfKWQkdgOYqRoWYLUPYXuLPy_mzLQrB-6LJb9A2YecMIbTjICSgXtfonQmteIsbvlG83GvvQ==\" rel=\"nofollow\" target=\"_blank\" title=\"anti-obesity drugs market\">anti-obesity drugs market<\/a>, focusing on the companies that lead it and the investments, pipelines and deals that will decide its future. The market is valued at USD 8.96 billion in 2026 and is forecast to reach USD 64.96 billion by 2035.<\/p>\n<p>Two companies set the pace. Eli Lilly&#8217;s third-quarter 2026 revenue rose 39% to USD 24.4 billion, with Mounjaro at USD 10.7 billion and Zepbound at USD 5.4 billion, and its oral GLP-1 Foundayo, approved on April 1, 2026, has started to add sales. Novo Nordisk&#8217;s obesity sales rose 22% at constant exchange rates to DKK 26.1 billion, helped by the Wegovy pill launched in the U.S. in January 2026. Both companies raised their 2026 outlooks.<\/p>\n<p>Challengers are investing heavily to catch up. Pfizer completed its acquisition of Metsera for up to USD 10 billion, Roche signed a USD 5.3 billion collaboration with Zealand Pharma, and Amgen has started Phase 3 trials of MariTide. Meanwhile, the leaders are building new pipelines and plants: Lilly&#8217;s retatrutide delivered up to 22.6% weight loss in Phase 3, Novo has filed CagriSema with the FDA, and Lilly is investing USD 50 billion in U.S. manufacturing. This release profiles the top companies and what their moves mean for competition through 2035.<\/p>\n<p><b>Full report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kw8DjiT45ZBGx8cDQytERa4YjUJ70Ov3lAROQbERCVKFvPvP-g-jYDD68tFvpT2js8Qpeny-nKa-E1HL6T-aZ8LpWyDHQ0JouDnQPGiSseFZV61SOSXJEUIhTheSt2owstdJ6oO7lHGdn5aTtM-NsTKCTXKxXSD9uK0hYyB643Xx0LdQhwrs7KejOQLX39y1s_nZCzN6--D9aFcp196e-A==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/anti-obesity-drugs-market<\/a><\/p>\n<p><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Kw8DjiT45ZBGx8cDQytERa4YjUJ70Ov3lAROQbERCVI-aE9iv4neB04jZ9uU3pCnGaGZMJiKQtp7vmgs4xsbodbD2VyexwArBi9FwQwmZ6G91IL7NgfydP4g_bZmQFWGo8wSvzZV0U0Am_9cP_hzcyKjfNToGDydI9VFdh6PrUM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/4896<\/a><\/p>\n<p><b>Market at a Glance<\/b><\/p>\n<table style=\"border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Market Indicator<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \"><b>Value<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2025 \u2192 2026<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 7.14 billion \u2192 USD 8.96 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market size, 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 64.96 billion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CAGR, 2026\u20132035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">24.71%<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. market, 2025 \u2192 2035<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">USD 3.59 billion \u2192 around USD 33.17 billion (24.90% CAGR)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest region \/ fastest-growing region<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">North America (more than 67%) \/ Asia Pacific<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Largest type \/ leading channel<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; vertical-align: top ; \">Prescription drugs (92%) \/ retail &amp; online pharmacy<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/86d6a087-d671-4cb0-8380-1bbfdb330b4f\/image3.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image3.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 1: Anti-Obesity Drugs Market Snapshot<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Prescription GLP-1 and dual-agonist therapies make up almost all revenue, and North America accounts for more than two-thirds of it. Asia Pacific is the fastest-growing region as Lilly, Novo Nordisk and regional developers such as Innovent, LG Chem and Zydus expand there.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Top Companies in the Anti-Obesity Drugs Market<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/013de0c8-9988-4dd3-8347-663f6c0a146b\/image4.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image4.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 2: Top Anti-Obesity Drug Companies, Latest Results (Q3 2026)<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Key Products \/ Assets<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Reported Data<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Position<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Eli Lilly<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Zepbound, Mounjaro (tirzepatide), Foundayo (orforglipron), retatrutide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 revenue USD 24.4B (+39%); Mounjaro USD 10.7B (+65%); Zepbound USD 5.4B (+49%); Foundayo USD 184M<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Market leader; 2026 revenue guidance raised to USD 91\u201392B<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novo Nordisk<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Wegovy injection, Wegovy pill, CagriSema<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Q3 2026 obesity sales DKK 26.1B (+22% CER); Wegovy pill DKK 5.4B; Wegovy injection DKK 20.4B (-2% CER)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">No. 2; pill launched in 8 markets; outlook raised Nov 4, 2026<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Metsera pipeline<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Acquisition completed Nov 2025 (up to USD 10B)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Re-entering obesity with long-acting injectables<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Zealand Pharma collaboration<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 5.3B deal (May 2025)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Building an amylin-based franchise<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Amgen<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">MariTide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Phase 3 program launched, including a 1,200-patient switch study (May 2026)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Targets less frequent dosing<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">AstraZeneca \/ Boehringer Ingelheim<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Clinical-stage candidates<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key players in the report<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Next-generation mechanisms<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rhythm Pharmaceuticals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Setmelanotide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rare genetic obesity<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Niche specialist<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Innovent \/ LG Chem \/ Zydus<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Regional candidates<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Named key players in the report<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Asia Pacific challengers<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>Lilly and Novo Nordisk hold a lead that other companies will struggle to close before the end of the decade. Lilly is growing faster, with tirzepatide sales rising in every region and international Mounjaro revenue up 93% in the third quarter. Novo Nordisk is shifting its growth to the Wegovy pill, which recorded about 3.6 million prescriptions in the quarter and more than 8 million since launch, while injectable Wegovy sales were slightly lower.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Pipelines: The Next Generation of Obesity Drugs<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Candidate<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Mechanism \/ Format<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Latest Milestone<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Eli Lilly<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Retatrutide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Triple agonist (GIP, GLP-1, glucagon), weekly injection<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Phase 3 TRIUMPH-3: 21.6\u201322.6% weight loss at 80 weeks; FDA filing planned Q1 2027<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Eli Lilly<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Foundayo (orforglipron)<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oral small-molecule GLP-1, no food or water restrictions<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">FDA approved April 1, 2026; Q3 sales USD 184M<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novo Nordisk<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CagriSema<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">GLP-1 plus amylin, weekly injection<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Filed with FDA Dec 2025; 22.7% weight loss in REDEFINE 1<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Novo Nordisk<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Wegovy pill<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Oral semaglutide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">U.S. launch Jan 5, 2026; DKK 10.9B in 9M 2026 sales<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Amgen<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">MariTide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Long-acting GLP-1 antibody-peptide<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Phase 3 trials started (2026)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pfizer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Metsera assets<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Long-acting injectables<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Acquired Nov 2025<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Roche \/ Zealand<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Petrelintide program<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Amylin analogue<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">USD 5.3B collaboration (May 2025)<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The pipeline shows where competition is heading: higher weight loss (retatrutide and CagriSema at more than 20%), pills that are easier to take and to manufacture, and longer dosing intervals. Companies that combine strong efficacy with convenient formats and manufacturing scale will capture the most share.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Investments and Deals<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/0f24eca2-ae1a-42c6-a82b-6d9ffd1a03df\/image5.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image5.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 3: Company Investments and Deals in Obesity<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Lilly is building scale.<\/b> Lilly has committed USD 50 billion to U.S. manufacturing across ten sites announced since 2020. In September 2026 it broke ground on a USD 6.5 billion Houston plant that will make Foundayo and other medicines.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Pfizer bought its way back in.<\/b> Pfizer completed the acquisition of Metsera for up to USD 10 billion in November 2025, after ending its own oral GLP-1 program.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Roche partnered for amylin.<\/b> Roche&#8217;s USD 5.3 billion collaboration with Zealand Pharma gives it an amylin-based candidate to combine with its own programs.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Novo is investing to defend share.<\/b> Novo Nordisk expects about DKK 50 billion in capital expenditure in 2026 and has launched the Wegovy pill in eight markets.<\/li>\n<\/ul>\n<p>These investments show that manufacturing capacity and access to new mechanisms are now the main competitive levers. Building peptide and oral manufacturing capacity takes years, which protects the leaders but also creates opportunities for contract manufacturers and device suppliers.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Company Developments<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"310.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/d63ef1e2-6983-4df6-9666-9927102666a3\/image6.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image6.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 4: Top Company Moves in Anti-Obesity Drugs, 2025\u20132026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Pills are changing the market.<\/b> Novo&#8217;s Wegovy pill launched in the U.S. on January 5, 2026, at self-pay prices of USD 149\u2013299 a month and is available at more than 70,000 pharmacies. Lilly&#8217;s Foundayo was approved on April 1, 2026, as the first daily GLP-1 pill without food or water restrictions.<\/p>\n<p><b>What it indicates:<\/b> Oral drugs widen access in primary care and emerging markets, and the competition between the two leaders is moving from injections to pills.<\/p>\n<p><b>Prices are falling as volumes rise.<\/b> Pricing agreements announced in November 2025 opened Medicare coverage for eligible patients and set prices around USD 245 a month for government programs.<\/p>\n<p><b>What it indicates:<\/b> Revenue growth will come from more patients rather than higher prices, rewarding the companies with the largest supply.<\/p>\n<p><b>Late-stage data are raising the bar.<\/b> Lilly reported in July 2026 that retatrutide produced up to 22.6% weight loss at 80 weeks in TRIUMPH-3, and Novo&#8217;s CagriSema showed 22.7% weight loss in REDEFINE 1.<\/p>\n<p><b>What it indicates:<\/b> New entrants will need to match more than 20% weight loss or offer clear advantages in dosing, tolerability or cost.<\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Key Market Drivers<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Rising obesity prevalence and related heart, kidney and metabolic disease.<\/li>\n<li style=\"margin-bottom:4pt;\">Strong clinical results from GLP-1, dual and triple agonists.<\/li>\n<li style=\"margin-bottom:4pt;\">Oral formulations and lower prices that widen access.<\/li>\n<li style=\"margin-bottom:4pt;\">Medicare coverage, employer programs and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-d39I5QkYVwT0Mlc4_9qpqFG3oUYy4PA1y-6ZQfzFWg7TfEgL7Uh3-rzNVrmPshqTfkdDEltUMCZ45aS1LadF3j0kMHbMb4lFDelCG9lIa69JVekAnREdao80yOrAqA0\" rel=\"nofollow\" target=\"_blank\" title=\"ePharmacy\">ePharmacy<\/a> and telehealth channels.<\/li>\n<li style=\"margin-bottom:4pt;\">Large manufacturing investments that ease supply limits.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Major Challenges<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">High long-term costs for payers and employers.<\/li>\n<li style=\"margin-bottom:4pt;\">Side effects, discontinuation and weight regain after stopping therapy.<\/li>\n<li style=\"margin-bottom:4pt;\">Peptide, pen and fill-finish capacity limits.<\/li>\n<li style=\"margin-bottom:4pt;\">Compounded and counterfeit products.<\/li>\n<li style=\"margin-bottom:4pt;\">Strong dominance of two leaders, which raises the bar for new entrants.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Emerging Opportunities<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Oral GLP-1 therapies<\/b> for primary care and emerging markets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Triple agonists and amylin combinations<\/b> for greater weight loss.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Longer-acting injectables<\/b> with monthly or less frequent dosing.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Asia Pacific<\/b>, the fastest-growing region.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Contract manufacturing and devices<\/b> for peptides, pens and oral products.\n<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Company Ecosystem<\/b><\/p>\n<p align=\"center\" style=\"text-align:center;\"><img decoding=\"async\" height=\"446.0px\" name=\"GNW_RichHtml_IMG\" src=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/170c8a89-a46d-4523-b4a0-1f3c20cb271a\/image7.png\" width=\"620.0px\" data-dpi=\"200\" data-filename=\"image7.png\" \/><\/p>\n<p align=\"center\" style=\"text-align:center;\"><b>Figure 5: Anti-Obesity Drugs Company Ecosystem, 2026<\/b><\/p>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p>The supply side combines the two market leaders, large pharmaceutical challengers, emerging developers such as Viking Therapeutics, Structure Therapeutics and Terns, and a manufacturing base that includes Novo Holdings&#8217; Catalent, Thermo Fisher, Lonza and device makers. The demand side includes pharmacies and telehealth platforms, payers and PBMs, employers and care providers.<\/p>\n<p><b>Customer and Buyer Intelligence<\/b><\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Target Account Group<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Decision-Makers<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Purchase Signals<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Commercial Opportunity<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharma business development<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Head of BD, Metabolic R&amp;D Head<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pipeline gaps, competitor data<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">In-licensing and acquisitions<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Employers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CHRO, Benefits Director<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Rising GLP-1 claims<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Managed coverage programs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Health plans and PBMs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Chief Pharmacy Officer<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Price agreements, oral launches<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Formulary and utilization contracts<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Pharmacies and telehealth<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Category and Operations Heads<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Self-pay demand for pills<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Direct-to-consumer fulfillment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">CDMOs and device makers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">BD and Operations Heads<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Plant announcements<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Peptide, oral and pen supply<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>How Precedence Research Supports Decision-Making<\/b><\/p>\n<p><b>Master Dataset<\/b> provides company, segment and regional data for obesity drugs and adjacent markets such as the <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HmKlT2aLuL5iZWkgDN9vE-EA4HenlV6i5FYjegDuahfMyqeSFlje0nNP7TwuQmf238UmHOZ4m37wkyL5m52VOA635QYS47I6PtwQ_izEnmh4PehQc0KbL00XMomgguxgKB6ckXVwA3Cpk8sjFck0GfvFqEKMR6obfRhNAwBlkvs=\" rel=\"nofollow\" target=\"_blank\" title=\"anti-obesity medication\">anti-obesity medication<\/a>, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3CWU7OMaNaZYUHHGw7f-nndlUZAuF0-hm2hWAn8xJRenBCWlPRYmyPOiQLYkQwmgji5FLHGqGp3fG1y02s773O95dQE27LoaAOmtXlJ9f4fQApkcHTlNMEwjSddjceZvZybQvPt0Xq1YLbPet6Y9lA==\" rel=\"nofollow\" target=\"_blank\" title=\"pharmaceutical\">pharmaceutical<\/a> and <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3CWU7OMaNaZYUHHGw7f-nrGAgyl7Pkl9LRuXiSaytl9Xkm21nPiWt-3j0qeFDgKO34S_dsysdl7x-G720xsuGXGn-Toq_NdzXvDW9fgfCG-jo4wo_HyOgdQNZdmO4lJP\" rel=\"nofollow\" target=\"_blank\" title=\"pharmacy\">pharmacy<\/a> markets. It helps teams size each company&#8217;s position by product and region.<\/p>\n<p><b>Precedence Quadrant<\/b> ranks obesity drug companies on sales, pipeline strength, manufacturing scale and access, helping business development teams and investors screen leaders and challengers.<\/p>\n<p><b>Interactive Intelligence Dashboard<\/b> tracks company results, approvals, trial readouts, price changes and deals, so teams can respond to competitor moves quickly.<\/p>\n<p><b>Quality &amp; Manufacturing Intelligence<\/b> maps company and CDMO capacity for peptides, oral products and devices, supporting supply and partnering decisions.<\/p>\n<p><b>Customized Research<\/b> answers specific questions, such as competitor benchmarking, pill versus injection uptake or partner screening in Asia Pacific.<\/p>\n<table style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; border-collapse: collapse; width:100%; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>Solution<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>What It Provides<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \"><b>How It Helps<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Master Dataset<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Company, segment and region data on obesity drugs<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Sizes each company&#8217;s position<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Precedence Quadrant<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Ranking of leaders and challengers<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Screens partners and acquisition targets<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Interactive Dashboard<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Live tracking of results, approvals and deals<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Times competitive responses<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Quality &amp; Manufacturing Intelligence<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Company and CDMO capacity mapping<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Supports supply and partnering<\/td>\n<\/tr>\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Customized Research<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Benchmarking and uptake studies<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; vertical-align: top ; \">Answers decision-specific questions<\/td>\n<\/tr>\n<\/table>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Why Continuously Updated Intelligence Matters<\/b><\/p>\n<p>The competitive picture in obesity changes every quarter. Monthly updates suit teams tracking prescriptions, prices and launches. Quarterly updates match Lilly and Novo Nordisk earnings. Six-monthly updates follow trial readouts and FDA decisions such as CagriSema and retatrutide, and annual updates support investors reviewing company share and market size. Precedence Research offers all four update cycles.<\/p>\n<p><b>Strategic Outlook<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>CEOs and CXOs:<\/b> Lilly and Novo Nordisk will lead through the late 2020s; challengers must differentiate on dosing, tolerability or price.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Strategy and business development teams:<\/b> deals such as Pfizer\u2013Metsera and Roche\u2013Zealand set valuations for late-stage obesity assets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>R&amp;D leaders:<\/b> more than 20% weight loss is becoming the efficacy benchmark; orals and long-acting formats are key.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Procurement and supply teams:<\/b> secure peptide, pen and oral manufacturing capacity early.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Investors:<\/b> emerging developers with differentiated mechanisms remain prime acquisition targets.<\/li>\n<li style=\"margin-bottom:4pt;\"><b>Manufacturers and suppliers:<\/b> Lilly&#8217;s USD 50 billion U.S. build-out and Novo&#8217;s capital spending drive demand for equipment and contract services.<\/li>\n<\/ul>\n<p><i>Sources: Expert Interview, Secondary Sources, Precedence Research Database, Precedence Research Analysts and Researcher<\/i><\/p>\n<p><b>Call to Action<\/b><\/p>\n<p>To compare the top anti-obesity drug companies and track their next moves, explore the full report or speak with a Precedence Research analyst.<\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\"><b>Report:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzwVD_K_Tb1q9bj7ag3upObah4efOgBECKg0oXCwANJQ7RUI4IW2HqXzCQR7huFL_USRjgo9NjDrZCKAuITWHvRa5ORaBL984N5YL1IsRY1XsbDwJwfe9as8a9QR1MYJGKoNueoWYdS1H1Rv8TZ3G6d\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/anti-obesity-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Request a sample:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEySki6BGCaHIgQAM5b8JE1BnRAF2NS9LwcHboIJTr-wW2ZPGKXd-SBULh_v0riK2u3hCu1VjF3rwYd8UB8MMGNnHUoeNMCISQz6tU_u4lXWIxb__mVZQt3ZBMmkO9-zo5Y=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/sample\/4896<\/a><\/li>\n<li style=\"margin-bottom:4pt;\"><b>Schedule a meeting:<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEyBMxGNDMOJtUZZ-ApB5Bn6JCm6dnaCZnfyXChStDQmjR5qQXvjI6IUFK4OwrxOT5y05zD2jbMstEeW8XAKkma6hzSZ0f0uPlscr9K2uvi1I-xuDZ-7U9fNg-mXCNo2zL0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/schedule-meeting<\/a>\n<\/li>\n<\/ul>\n<p><b>Fill out the form for relevant samples, case studies, and examples.<\/b> <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=cbzgdiKmh-8hVIpvzaF17NbLgulW4NqkvXVu2JcG2VcH05cOOSYC4j3jjQCHyhQKPidE6Q5n0dSYc37GPdC211IZTvdHBvEMVZmV4U4Ai6G4wY-ugGaglemzaIFx3sid\" rel=\"nofollow\" target=\"_blank\" title=\"sales@precedenceresearch.com\">sales@precedenceresearch.com<\/a><\/p>\n<p><b>Related Reports<\/b><\/p>\n<ol style=\"list-style-type:decimal;\">\n<li style=\"margin-bottom:3pt;\">Anti-Obesity Medication Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzwVD_K_Tb1q9bj7ag3upObYreB-5bWTL0ahckf0yJuXDK9kd2dOCvIzr-BHivFNJhZAKnAw3gCtyGGpmOMT8QL7FW4pixXT6VWv31IkD2f_gg0ZGwsNUmorajZhNKpGeg6sioDJsHtbfLXIjf-UYSX4fkxcu9bLGXigvXF8wiEFA==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/anti-obesity-medication-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Over the Counter Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEw6Anq6F-Jb96_iE_yq2oWiHx7YoGfm7IV4sAmQu4Aqjp2CVljNNJDhHSjB24egeTeM3S-7gg7vY0Oy9WWBDW5hMJPkjKGxamsGVuRetPBNjLHuMUGhWSs1AuuHqhp2erMqPwIkY5-vb5SSXebf2o6tybNsggFot0fZlVCyIB1aUw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/over-the-counter-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">U.S. Over the Counter Drugs Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEwUWsOYZFD46qcpA0mWj3_FNmQPen_k9J7rgV-ROgdyplHhczyqRVnTuMoUazP-VkezeD4emY33R9LQg56xrJPifCuGPCYYNYVdOLzh6SUiCgbFwI-9WSTMxBcGJJx8vOD7xGlZxFbJz4M8ZrGIiemnO5eUreeKbsjJYSgt-f4MLg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/us-over-the-counter-drugs-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzWddMdunz4MR97lWIe0PdSctWO82xd--iGWF6FgtM9bIRXHUuZTYzWYLsM0bhZ8zqNcd8F5qRIEUZlo-7agePDRLD2JgKOyhbaxzYKyqGUf9Wp0Gts5XOpeNDC6VLH7stJ21AIe8DCECI7dTMrpG_k\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biopharmaceutical Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEw06qxo-MT6tWib4NKAFQkhPMbuSRYTtkO19qAcu7kT2vPrXNsDXAUBQXrJutK-VcBwlAD1hu84JxZnm5VkMZi3e1GbrIWQac4xbM8V6Qa-c-lBdZYdujHQV_xoHp9eeGN9Dy3uWOGl0vpsFd2TXGV9\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biopharmaceutical-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Biotechnology Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEw06qxo-MT6tWib4NKAFQkhZiXFRSbA0YFEg-BgBRpfEbOygitAF7XR_G6iY0UaXq8bJNLy5jhgASCqBwBhBKPtjZ45eomSDFZ3E7zP-U5684HoQwqQL-wSo9XhX4oY_LE4_LMsx50hW2pMEeTV4SIk\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/biotechnology-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmacy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzWddMdunz4MR97lWIe0PdSLqKWR-AO8hNUrE8Os-zUEuy0BYmNTTYSTYm76pHfi-aJDkt7qB4TH9uxFbAi6G5hCaFZ9oLqigrsedGeqobZFIOHoy6Hwaeh0yiCcFILo4Q=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmacy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">ePharmacy Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEw3uWLgasIhm-XIZVsSUuA4bRZXQz5O8SkFPreEK9tyaO4WMw42yXLJ369u2isIzfD2WTE-qRbj3uKPrqUJoAqEgtrUOds1sEfyrnqf_7ZygJdeU2OzHzJ7YXK9qgaAAcM=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/epharmacy-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmacy Automation Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzWddMdunz4MR97lWIe0PdSGAsoAPjDIZ6BYdXWNAZTR6K3QQAmb_tnkIWTHyHXLjeK6yOYo220oDz76li0P26i23wZ9h7l4CqklLDgBoIvCjy3SwJo65terEbcNXFErZH-abe5joDzcke4RW8Yk6dtE6kMUUirpbfeshgC5wr-Hw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmacy-automation-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Pharmacy Benefit Management Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzWddMdunz4MR97lWIe0PdSnoisYNWEHLTiVJuIKiQn_n0FJcxgr_7H3rSQUC6w_3atv1VelMiFrwE5S0Ov6yGQLlpdu8gRjkNZxFD_h9XS8f6DnFh-e5P1aLWfX7hcYSbtpCfhgu81KGMJxsqe22joCdJuMM6fcSrt8Jf7oBsfXbrpovAlH9xXkRwaUCDIdjk=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/pharmacy-benefit-management-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">U.S. Pharmacy Benefit Management Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEwUWsOYZFD46qcpA0mWj3_FJMcWl2sPeMPJ_uDd5aanv1SWH0u8eOQ-WjUeowx8A59hnyQi_uAbfMn11IbnqTajEuN2NT5cbBNz5jGx7E3Bjr-WKEguoXHaRJUMmImrPnXvE0MSystZf1nox0KPNhketp2a0iNvwkjEirU5kfgNz47_JkZLtOTlLkm9CU6fWg0=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/us-pharmacy-benefit-management-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Health Insurance Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLExsizF6HxoR2zUpUyGqEynaLdXLu9839b9X5B31RzzP02CTTt6GpvxpY5Wq2XqpX-Pzqdmi0VJBrVFMtr64KnjTdkjs93dC1eRxMhcf_PBsvstDcZ5jfsy5_cXjW0uqVHFyR1hIGuJ3lkBmNyY_71J9\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/health-insurance-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Healthcare Payer Services Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLExsizF6HxoR2zUpUyGqEynaodxg4IsNkc3FeK6R6x4jOlYZkt2DXcCg6gZ527G_gAzcS1kMqgS713qNdu6IMknoeiWgCwowcQ5_5eYCKZc_L5UMiLk-LLFVbrx8lVw29JrrrHKftW2mRosX6fkD106-W0yctBMf8zq5TIlnN25ixw==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/healthcare-payer-services-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Digital Health Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLExwblnwNlFbTSu-6PlA7uZSmkQf7NdhneutKEw5Dd8UiFsihN_qSFxuV_cU3mUPmKAoOtwh2YZYFhxRyPVQLd2wx40FGzim7_mB8zrkqSdDHMYrOSWosX-b32MtSb2-b5uR3mKiZSa5GN9pp7rYDjZA\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/digital-health-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Population Health Management Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEzAjMaz546dVpPb_eLec91HIjxR_b7l08rEIsAlvybk0dub-S2V5TG5gWG1jo1JaGGQJNlFmVFWd10WK_7PYiZ4HOkvDd9xreruhd7Yp9XARlLuS1osDdHwzj8VWIbXLkM0w4U3uqBazo70G9pTDMARu52aTXySoPMsOgWR8yCvCpSad2l9pC1Fm1haJt0rFvI=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/population-health-management-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Healthcare Analytics Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLExsizF6HxoR2zUpUyGqEynannr5zwTZk6LYL04JpkEYmRCxfW6Nofhf_Ce4fHccRW2gAs0c6cQD0Z_RsmVv_4IUKHncHnyOKxXpKx0pUmrlo4el5Pfn5TSE3aoIdeC1Sct83M-B9EvRJrBwXBACdkn_IzN7bavpQMNtBpKo8kN7Eg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/healthcare-analytics-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Precision Medicine Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEx5_SGXhsTSKbS9cm3jCj0sWzOPyovKSTYqHHZK2dsB9e25veVWKJjrdlZDWa3T4HIdws2ztXVnV0c1nYtGVshO0HF2_06s3gD9xtPbUhYJP3osthFalxFND40QJOc6w_isLV0UhZEIbtuNobU9eLfV\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/precision-medicine-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Clinical Trials Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLExlcU5mTk-CrqYS9dCMn2B5arsxM6bJAmLcWu_NrJi4iKwJ4j00YZYQsoGqpMqQ8i_Eq7n5zdKLzxRJA6L5_RHaHLTb43go26bdZghvTyzo_P6yXR-jRlhfyIut0n_lMTHG1soORvng4FKoz55O2J8R\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/clinical-trials-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Monoclonal Antibodies Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEy3Neu3zGoKngT8t2Ct0TVGXxjzs7wq8f9BmUzM56J4KcJn85Wg7xmi53-qBDQyY3TpTfY3xZJ0GKKSlPBBTn5nYELW8pjO3zc_RfiayZ8X5CAkWkzjQ2_GJLIpFlDz_TTOXAJQtzTfA5U0cUg_1_e9T5FEIv_1sa0rGhRpey-BMg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/monoclonal-antibodies-market<\/a><\/li>\n<li style=\"margin-bottom:3pt;\">Artificial Intelligence Market: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_MBWbo9KgnAOAaxl1njLEx2TQVXV4ad8PiGdUBwOSy46ckD-xSdPKQs6VlIKIw1q6H-9TNLYdnmRddX5kv5m7tZUdTTGcoVnUSzRm0RvFP-bMeVUNDdnvaz8EQN0Jbw8fiBiqsaHonYE0C3jxSiZNP6vGoSzg5Qdkwr7wUqvtNm2loMGJvvB5fbbiS7swlYnQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.precedenceresearch.com\/artificial-intelligence-market<\/a><\/li>\n<\/ol>\n<p><b>About Precedence Research<\/b><\/p>\n<p>Precedence Research is a global market intelligence and consulting company. It provides market sizing and forecasts, competitive and company analysis, customer and buyer intelligence and customized research across healthcare, pharmaceuticals, consumer health, ICT, energy, chemicals and materials and other industries, helping executives and investors make evidence-based decisions.<\/p>\n<p><b>Our Partners<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">Towards Healthcare: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe82hF7hsIWh1CUCXtWptRVoaEPQAufeWzULNC32hfbAoZbUE4dE2uN4Q5HIp7-G-wdmP5GOJtW0bcWwpppb88fGLuFKezSNiu-215TzDnEtQc\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardshealthcare.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Packaging: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8xVHHY5rLOCJiUJ-9fN5rRQEDWlRIfq4tTf-gv-ipqQLxMHsNXR-jt8bjeCPWgs56vI7C9MrPRJUjWmT7cwvKisx639aX4VwfBH-t1e4FSeG\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardspackaging.com\/<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Towards Chemical &amp; Materials: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe85LK5qifSAEHzA9hyiPfrOXl_CDbwQhRfZqxhK4j4f5HY4yKvMw3Ff-ElYc5Kl24pPmPsHF_EJYRxOMHyLXuBAjlcCikeFKAOkn7uw0VnuUse8eEHmbpjReog3nLf4Uc8w==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.towardschemandmaterials.com\/<\/a>\n<\/li>\n<\/ul>\n<p><b>Connect With Us<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">USA: +1 804 441 9344<\/li>\n<li style=\"margin-bottom:4pt;\">APAC: +61 485 981 310 or +91 87933 22019<\/li>\n<li style=\"margin-bottom:4pt;\">Singapore: +65 3105 1271<\/li>\n<li style=\"margin-bottom:4pt;\">Europe: +44 7383 092 044<\/li>\n<li style=\"margin-bottom:4pt;\">Email: sales@precedenceresearch.com\n<\/li>\n<\/ul>\n<p><b>Social Media<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-bottom:4pt;\">LinkedIn: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe8_SUivT3NhPvdGkmzXJpADdiEKl_WTuxmtyFmXaZhjPn4O1kFuzC7ctFQqw86fq1IfYiwe5thBUj4npKOuykZXdoWs13lIwQu_xP50Gfo_zYS58F4swrllsVYMSpV11iCd_MhMPvazPdOBse8WRnq_g=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.linkedin.com\/company\/precedence-research<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Facebook: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe89154nMmYrFcYBdt4ohMtzly-tfc7GqR5WvnHl0MELj0a0814pS-OMsDErobxIlNraV9hFX0pIvhkingVgtheiwCoTTrLCqixc7mguXwevGLD4I0rzfCnd0iuZVWXB-w9Q==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/www.facebook.com\/precedenceresearch<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">X: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe88qtR3WC_pGObccIUEsmRUw_86e-0zKdNADbphpcnkEcZ72yGEhZZelaxK324dHjHT1GwnSoDK63Zh6R-ynjNmE=\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/x.com\/precedence_r<\/a><\/li>\n<li style=\"margin-bottom:4pt;\">Medium: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9KEgPGiW1BBAaok7hyKe87Q7HAebYLhtvbscvzC-a4XmsNsNdhRQBm-7rct0sawoahwvGTnDq4ZWLkO2LHU5g3Ippqf8AO6rJqx-bX1I4kZtIWD8zHkyUi75rHUw0SUemiZAJfUJreYeYO_DvyiHNg==\" rel=\"nofollow\" target=\"_blank\" title=\"\">https:\/\/precedence-research.medium.com\/<\/a><\/li>\n<\/ul>\n<p><img alt=\"\" src='https:\/\/ml.globenewswire.com\/media\/YjEzMDU1ZjktMzQ3Yy00NjllLWJhNzktZTA0NzY0YzU3YTAyLTEyMTM4NDktMjAyNi0xMS0xNi1lbg==\/tiny\/Precedence-Research.png' referrerpolicy='no-referrer-when-downgrade' \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lilly&#8217;s Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo&#8217;s Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: Precedence Research Company Intelligence on Leaders, Pipelines, Investments and Deals Ottawa, Nov. 16, 2026 (GLOBE NEWSWIRE) &#8212; The global anti-obesity drugs market is valued at USD 8.96 billion in 2026 and [&#8230;]\n","protected":false},"author":1,"featured_media":91233,"comment_status":"open","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"footnotes":""},"categories":[20],"tags":[],"class_list":["post-91232","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globe-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035 - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035\" \/>\n<meta property=\"og:description\" content=\"Lilly&#8217;s Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo&#8217;s Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: P\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2026-11-16T15:37:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-11-17T02:15:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035.png\" \/>\n\t<meta property=\"og:image:width\" content=\"237\" \/>\n\t<meta property=\"og:image:height\" content=\"77\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035\",\"datePublished\":\"2026-11-16T15:37:00+00:00\",\"dateModified\":\"2026-11-17T02:15:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\"},\"wordCount\":2372,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Globe Newswire\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\",\"name\":\"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035 - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2026-11-16T15:37:00+00:00\",\"dateModified\":\"2026-11-17T02:15:03+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035 - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/","og_locale":"en_US","og_type":"article","og_title":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035","og_description":"Lilly&#8217;s Mounjaro and Zepbound Earn USD 16.1 Billion in One Quarter, Novo&#8217;s Obesity Sales Rise 22% and Oral GLP-1 Pills Open a New Front: P","og_url":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2026-11-16T15:37:00+00:00","article_modified_time":"2026-11-17T02:15:03+00:00","og_image":[{"width":237,"height":77,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/11\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035","datePublished":"2026-11-16T15:37:00+00:00","dateModified":"2026-11-17T02:15:03+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/"},"wordCount":2372,"commentCount":0,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Globe Newswire"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/","url":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/","name":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035 - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2026-11-16T15:37:00+00:00","dateModified":"2026-11-17T02:15:03+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/anti-obesity-drugs-market-companies-analysis-2027-eli-lilly-and-novo-nordisk-lead-as-pfizer-roche-and-amgen-invest-billions-to-challenge-them-in-a-market-headed-for-usd-64-96-billion-by-2035\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91232","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=91232"}],"version-history":[{"count":1,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91232\/revisions"}],"predecessor-version":[{"id":91234,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/91232\/revisions\/91234"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/91233"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=91232"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=91232"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=91232"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}